What’s ahead in the GLP-1 market in 2026 The obesity rate has been increasing over time in the U.S. From August 2021 to August 2023, about 40% of American adults were considered obese. A recent study shows that these rates will continue to rise for about 20 more years. Complications related to obesity include heart…
Beyond Diabetes and Obesity: The Expansion of GLP-1 Medications Glucagon-like peptide-1 (GLP-1) medications have revolutionized the treatment of diabetes and obesity, but their impact is rapidly broadening. Recent research and regulatory approvals reveal that GLP-1s may offer hope for a range of other health conditions, some of which might surprise you. Metabolic dysfunction-associated steatohepatitis (MASH)…
By Azim Bari, Chief Clinical Officer for Gateway Health Partners explains GLP-1s and Utilization Management With predictability and clarity at the forefront of everything we do, Gateway Health Partners is committed to sharing our insights and expertise to help you stay informed and navigate your options as GLP-1s continue to transform the healthcare landscape. The…